Back to Journals » Degenerative Neurological and Neuromuscular Disease » Call For Papers

Degenerative Neurological and Neuromuscular Disease


The following Article Collection/ Thematic Series is currently open for submissions:

Therapeutic options in chronic neurodegeneration: from experimental research to clinical practice

Dove Medical Press is pleased to invite you to submit your research to an upcoming Thematic Series on “Therapeutic options in chronic neurodegeneration: from experimental research to clinical practice", edited by Editor-in-Chief Professor Thomas Müller in Degenerative Neurological and Neuromuscular Disease.

Upon submission, please use the promo code WNGXX for 20% off the advertised article processing charge and indicate that your manuscript will be considered for the Thematic Series of "Therapeutic options in chronic neurodegeneration: from experimental research to clinical practice". The deadline for manuscripts is the 30th of September 2022.

For any enquiries, please email Assistant Journal Development Editor, Vicky Ship, at [email protected]

About the Thematic Series

Chronic neurodegeneration and associated chronic neuroinflammation are characterized by progressive neuronal loss over time. Neurodegeneration may cause brain atrophy and several related functional deficits. The importance of the brain as a powerhouse to a multitude of abilities, and arguably the trait that allows people to be “themselves”, can be slowly whittled away by cruel diseases. The origin of which is typically unknown outside of neurodegenerative diseases that are known to be hereditary.

Why are the causes so complex? How can the scientific and medical community proceed in treating them? From the early development phases, clinical trials, regulatory approval and real-world practice, developers have introduced therapeutic options for some neurodegenerative diseases. While chronic neurodegeneration may be heterogenous in nature, the development of treatments can provide reassurance for those affected.

This Thematic Series seeks to cover current treatment modalities and how they are used in clinical practice and to consider emerging therapies being developed for chronic neurodegeneration, alongside further developing an understanding of how these diseases affect individual abilities and functions. It is hoped that discussion of these issues can help researchers improve the lives of those enduring neurodegenerative diseases, such as Parkinson’s disease, and those that are rarer, including Creutzfeldt-Jakob disease.

The journal is seeking original submissions and review articles on the following topics related to the treatment of chronic neurodegenerative diseases and the journey of developing these therapies:

• Development processes of treatments for neurodegeneration
• Teachings from neuron destruction, brain atrophy and loss of function
• Differentiation between symptomatic treatment, disease modification
• Reaching the possibility of a cure
• Medication, immunology, antibody treatments and additional therapy options in development, in trials or available for patients

Submit your manuscript
https://www.dovepress.com/submit_step_1.php

View all papers in this thematic series


Call For Papers

Editor-in-Chief: Professor Thomas Müller

To see where Degenerative Neurological and Neuromuscular Disease is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Degenerative Neurological and Neuromuscular Disease?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Degenerative Neurological and Neuromuscular Disease has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.

PubMed Central
Degenerative Neurological and Neuromuscular Disease is indexed on PubMed Central (title abbreviation: Degener Neurol Neuromuscul Dis). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely,
Professor Thomas Müller
Editor-in-Chief
Degenerative Neurological and Neuromuscular Disease

Email: Editor-in-Chief